Aspira Women's Health Inc. has entered into a securities purchase agreement to sell 1,694,820 shares of common stock to various investors at different offering prices, aiming to raise approximately $4.7 million. The sale is expected to close on July 24, 2023, with no pre-funded warranties sold and limitations on further sales set for 90 days. Aspira has also agreed to pay fee and expense allowances to its placement agent, A.G.P./Alliance Global Partners.